Briguori Carlo, Donnarumma Elvira, Quintavalle Cristina, Fiore Danilo, Condorelli Gerolama
aLaboratory of Interventional Cardiology and Department of Cardiology, Clinica Mediterranea bFondazione SDN cDepartment of Molecular Medicine and Medical Biotechnologies, 'Federico II" University of Naples and IEOS, CNR Naples, Naples, Italy.
Curr Opin Nephrol Hypertens. 2015 Mar;24(2):145-53. doi: 10.1097/MNH.0000000000000106.
Contrast-induced acute kidney injury (CI-AKI) is an impairment of renal function following contrast media administration in the absence of an alternative cause. It represents a powerful predictor of poor early and late outcomes. Here, we review the major strategies to prevent CI-AKI.
Hydration represents the gold standard as a prophylactic measure to prevent CI-AKI, acting by increasing urine flow rate and, thereby, by limiting the time of contact between the contrast media and the tubular epithelial cells. An optimal hydration regimen should be defined according to predefined clinical markers, such as urine flow rate, or left ventricular end-diastolic pressure. Recently, high-dose statins pretreatment has been included in the guidelines of CI-AKI prevention. However, uncertainty still exists on the efficacy of several compounds tested in both observational trials and randomized studies to prevent CI-AKI. Compounds evaluated include diuretics (furosemide), antioxidants (i.e. N-acetylcysteine and statins) and vasodilators (i.e. calcium antagonists, dopamine and fenoldopam).
Hydration still represents the most reliable strategy to prevent CI-AKI. New prophylactic strategies for acute kidney injury are still under investigation.
对比剂诱导的急性肾损伤(CI-AKI)是指在无其他病因情况下,使用对比剂后出现的肾功能损害。它是早期和晚期不良结局的有力预测指标。在此,我们综述预防CI-AKI的主要策略。
水化作为预防CI-AKI的预防性措施是金标准,其作用机制是增加尿流率,从而限制对比剂与肾小管上皮细胞的接触时间。应根据预定义的临床指标(如尿流率或左心室舒张末期压力)来确定最佳水化方案。最近,大剂量他汀类药物预处理已被纳入CI-AKI预防指南。然而,在观察性试验和随机研究中测试的几种预防CI-AKI的化合物的疗效仍存在不确定性。评估的化合物包括利尿剂(呋塞米)、抗氧化剂(如N-乙酰半胱氨酸和他汀类药物)和血管扩张剂(如钙拮抗剂、多巴胺和非诺多泮)。
水化仍然是预防CI-AKI最可靠的策略。急性肾损伤的新预防策略仍在研究中。